Regeneron has secured the rights to Hansoh’s late-stage GLP-1/GIP receptor agonist [HS-20094] in a significant $2 billion deal. This acquisition enables Regeneron to explore synergistic combinations with its own drugs, aiming to tackle muscle loss and potential obesity-related comorbidities like cardiovascular diseases, diabetes, and liver conditions. Boaz Hirshberg, Regeneron’s senior vice president of clinical development […]